Facit exited McMaster University's cancer radiotherapy spinout in an upsized initial public offering after $158m in funding.
Fusion Pharmaceuticals, a Canada-based cancer drug developer spun out of McMaster University, raised almost $213m when it went public on Friday.
The initial public offering involved the company increasing the number of shares in the IPO from 8.35 million to 12.5 million and pricing them at $17 each, above the $14 to $16 range it had set the previous Monday. It floated on the Nasdaq Global Select Market.
Underwriters Morgan Stanley, Jefferies, Cowen and Company and Wedbush…
